Relapsed or Refractory Multiple Myeloma Clinical Trial
Official title:
A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
This open-label, Phase 1, dose-escalation, first-in-human (FIH) clinical study of mRNA-2736 in participants with RRMM is designed to evaluate the safety and tolerability of escalating doses of mRNA-2736, administered intravenously (IV), to determine maximum tolerated dose and/or recommended Phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mRNA-2736. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03837509 -
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05519085 -
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 3 | |
| Active, not recruiting |
NCT02099539 -
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00545519 -
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05052970 -
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
|
Phase 1 | |
| Completed |
NCT03464916 -
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
|
Phase 1 | |
| Recruiting |
NCT05455320 -
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
|
Phase 3 | |
| Withdrawn |
NCT05408026 -
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04684108 -
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT05652335 -
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
|
Phase 1 | |
| Completed |
NCT03859427 -
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01866293 -
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06375044 -
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01058434 -
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
|
Phase 2 | |
| Recruiting |
NCT04735575 -
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06298266 -
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
|
Early Phase 1 | |
| Recruiting |
NCT05572515 -
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 3 | |
| Active, not recruiting |
NCT04798586 -
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT02075021 -
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT00478777 -
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
|
Phase 3 |